Our Mission

Translating scientific discoveries into new medicines

Aditum is Latin for access—our mission at Aditum Bio is to give patients access to medicines that may not otherwise be developed.

Aditum Bio is an investment firm focused on acquiring and developing biotechnology assets that will benefit patients.

Co-founded by industry veterans Joe Jimenez, former CEO of Novartis, Mark Fishman, former President of the Novartis Institutes for Biomedical Research, and Paul Sekhri, former CEO of Lycera, the firm works in collaboration with TrialSpark, a tech-enabled platform that conducts innovative clinical trials faster and at lower cost than traditional clinical development organizations (CROs).

The Opportunity

Genetic, genomic and artificial intelligence have led to the discovery of new drug targets and therapeutic modalities; however, many drug candidates fail to be developed due to strategic decisions and high clinical trial expense.

Aditum Bio allows an alternative outlet for these discoveries as they advance into the clinic. We acquire these assets from biotechnology and pharma companies and develop them through Phase II utilizing TrialSpark as the innovative clinical research engine.

This fund has the following advantages:

Management Team

Joe Jimenez, Managing Partner and Co-founder, is the former CEO of Novartis. He managed one of the largest portfolios of drug assets in the industry. Dr. Mark Fishman, Co-Founder and Chairman of the Scientific Advisory Board, is the founding President of the Novartis Institutes for Biomedical Research. He successfully discovered and advanced multiple blockbuster drugs (e.g., Cosentyx, Entresto). Paul Sekhri, Co-Founder, is the former CEO of Lycera. Paul has a wealth of industry knowledge and experience in strategy and business development.
TrialSpark

TrialSpark is a technology company working to transform the speed and cost of running clinical trials. TrialSpark uses a novel operational model optimized by software, data, and machine learning. TrialSpark partners with physicians whose patients match specific trial criteria and then creates FDA-compliant trial sites embedded in those practices. By using technology to standardize operations at the trial site level, TrialSpark cuts out the manual CRO layer, enabling real-time readouts, adaptive trials, and significant cost and time savings.
Management Structure

Aditum Bio creates a lean management structure for its portfolio companies, significantly lowering their burn rates by using TrialSpark as the core operational engine for each asset.

Joe Jimenez

Co-Founder and Managing Director

Former Chief Executive Officer of Novartis, one of the world’s leading pharmaceutical companies. Under his leadership, Novartis developed one of the largest pipelines of drugs in the industry.

Mr. Jimenez is currently a member of the Board of Directors of General Motors Company and The Procter & Gamble Company. He graduated in 1982 with a bachelor’s degree from Stanford University and in 1984 with a Master of Business Administration from the University of California, Berkeley.

Dr. Mark Fishman

Co-Founder and Chair of the Scientific Advisory Board

Founding President at the Novartis Institutes for Biomedical Research (NIBR) (2002-2016). Mark C. Fishman, MD, is currently a professor of stem cell and regenerative biology at Harvard.

During his tenure, NIBR discovered and brought through successful early clinical trials 90 new medicines in more than 120 indications.

Prior to Novartis, while chief of cardiology and director of the Cardiovascular Research Center at Harvard Medical School and the MGH, Dr. Fishman’s research helped to introduce the zebrafish as a genetic model organism.

Dr. Fishman graduated from Yale College and Harvard Medical School and trained in medicine and cardiology at the MGH. In addition to his publications in developmental biology and drug discovery, Dr. Fishman is the author of the textbook, “Medicine”, and of the textbook “ Lab”, an architecture book on how to design buildings for scientists. He is a member of the National Academy of Medicine and a fellow of the American Academy of Arts and Sciences.